You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Skip to content

This site is a non-promotional medical portal for Kenya Healthcare Professionals. Not a healthcare professional? Visit our Public site

GSK Logo
Search

Report adverse event

GSK Logo

For Kenya Healthcare Professionals

  • GSK Medical
  • Therapy Areas
    • Vaccines
    • Respiratory
  • Contact us
Vaccines
  • Vaccinology
    • Introduction
    • Direct Benefits
    • Indirect and overall benefits
    • Economic Benefits
    • Conclusions
  • Vaccinology
    • Introduction
    • Direct Benefits
    • Indirect and overall benefits
    • Economic Benefits
    • Conclusions

Menu

  1. GSK Medical>
  2. Therapy Areas>
  3. Vaccines>
  4. Vaccinology>
  5. Adjuvants MoA in Vaccines

Adjuvants Mode of Action in Vaccines

A greater understanding of the role of the innate response in eliciting specific adaptive immunity has led to an increased knowledge of the role of adjuvants in vaccine formulation. Adjuvants enhance and modulate the immune response to antigens by mimicking natural immune defense triggers.2

Adjuvants as explained in the video below can be key contributors in developing efficacious vaccines aiming to deliver enhanced and sustained protection.2-5

References

  1. Leo O et al. In: Garçon N et al. Understanding Modern Vaccines, Perspectives in Vaccinology. Amsterdam: Elsevier; 2011. Vol 1. Chapter 2:25–59.
  2. Garçon N et al. In: Garçon N et al. Understanding Modern Vaccines, Perspectives in Vaccinology. Amsterdam: Elsevier; 2011. Vol 1. Chapter 4:89–113.
  3. Giannini SL et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006;24:5937–49.
  4. Roman F et al. Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials. Clin Vaccine Immunol 2011;18:835–43.
  5. Roteli-Martins et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine. Hum Vaccin Immunother 2012;8:390–397.

Material supplied by the above-country business unit to LOCs for localisation must be subject to local Medical and/or Regulatory review and approval prior to use and/or external distribution.

LOCs to insert local adverse events reporting procedure.

© 2022 GSK group of companies or its licensor. GlaxoSmithKline Biologicals SA. Rixensart, Belgium.

NX-GBL-GVX-WCNT-220017 | November 2022

Get in touch

 

Contact us

  • Report adverse event
  • Sitemap
  • Terms of use
  • Privacy Notice

©2024 GSK group of companies or its licensor. GlaxoSmithKline Export Limited, at 79 New Oxford Street, London, WC1A 1DG, UK.